These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33431338)

  • 21. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
    Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
    J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. This Time I Mean It!
    Tempero M
    J Natl Compr Canc Netw; 2020 Jan; 18(1):1. PubMed ID: 31910382
    [No Abstract]   [Full Text] [Related]  

  • 28. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
    Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
    Eckert JC
    Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA Oncology Center of Excellence Review Processes and Tools.
    Gao JJ; Kluetz PG; Pazdur R
    Clin Pharmacol Ther; 2020 Sep; 108(3):428-429. PubMed ID: 32654129
    [No Abstract]   [Full Text] [Related]  

  • 32. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.
    Gyawali B; Rome BN; Kesselheim AS
    BMJ; 2021 Sep; 374():n1959. PubMed ID: 34497044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
    Farha M; Masson E; Tomkinson H; Mugundu G
    J Clin Pharmacol; 2019 Apr; 59(4):463-471. PubMed ID: 30536979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.
    Jenei K; Raymakers A; Meyers DE; Prasad V
    J Cancer Policy; 2021 Dec; 30():100311. PubMed ID: 35559802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2.
    Beinse G; Tellier V; Charvet V; Deutsch E; Borget I; Massard C; Hollebecque A; Verlingue L
    JCO Clin Cancer Inform; 2019 Sep; 3():1-10. PubMed ID: 31539266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
    Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
    Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-drug associations: a complex system.
    Dalkic E; Wang X; Wright N; Chan C
    PLoS One; 2010 Apr; 5(4):e10031. PubMed ID: 20368808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.
    Manag Care; 2002 Jun; 11(6):56. PubMed ID: 12098877
    [No Abstract]   [Full Text] [Related]  

  • 39. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes in drug development for hematology.
    Acquadro C; Regnault A
    Hematology Am Soc Hematol Educ Program; 2015; 2015():496-500. PubMed ID: 26637764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.